Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG)

European Journal of Cancer

Volumn 41, Issue 1, 2005, Pages 98-103

  Groninger, Ellis ^a   Meeuwsen De Boer, Tiny ^a   Koopmans, Pauline ^b   Uges, Donald ^b   Sluiter, Wim ^b   Veerman, Anjo ^c,d   Kamps, Willem ^a   De Graaf, Siebold ^a,e  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Dutch Childhood Leukaemia Stud Grp   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute lymphoblastic leukaemia; Childhood; Pharmacodynamics; Pharmacokinetics; Response; Vincristine

Indexed keywords

ANTINEOPLASTIC AGENT; VINCRISTINE;

AB INITIO CALCULATION; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAYES THEOREM; BLOOD SMEAR; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CHILD; COMPUTER PROGRAM; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; INFANT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHARMACODYNAMICS; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BONE MARROW; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HALF-LIFE; HUMANS; INFANT; INFANT, NEWBORN; LETHAL DOSE 50; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; VINCRISTINE;

EID: 11144255819     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.10.006     Document Type: Article

References (24)

1. J.M. Chessells The management of high-risk lymphoblastic leukaemia in children Br J Haematol 108 2 2000 204 216
2. R. Pieters, D.R. Huismans, A. Leyva, and A.J. Veerman Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia Cancer Lett 41 3 1988 323 332
3. R. Pieters, D.R. Huismans, A. Leyva, and A.J. Veerman Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukaemia Br J Cancer 59 2 1989 217 220
4. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Methods 65 1-2 1983 55 63
5. G.J. Kaspers, A.J. Veerman, and R. Pieters In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia Blood 90 7 1997 2723 2729
6. D. Pinkel, K. Hernandez, and L. Borella Drug dosage and remission duration in childhood lymphocytic leukemia Cancer 27 2 1971 247 256
7. W.E. Evans, J. Rodman, and M.V. Relling Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia Semin Hematol 28 3 Suppl. 4 1991 15 21
8. Z.R. Desai, H.W. Van den Berg, J.M. Bridges, and R.G. Shanks Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 8 2 1982 211 214
9. Gidding CE, Fock JM, Begeer JH, et al. Vincristine disposition and neurotoxicity in children. Abstract N22-2068-ASCO 1998. 16-5-1998
10. L.J.C. van Warmerdam, B.J.F. van den Bemt, W.W. Ten Bokkel Huinink, R.A.A. Maes, and J.H. Beijnen Dose individualisation in cancer chemotherapy: pharmacokinetic and pharmacodynamic relationships Cancer Res Ther Cont 4 1995 277 291
11. W.E. Evans, M.V. Relling, J.H. Rodman, W.R. Crom, J.M. Boyett, and C.H. Pui Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia N Engl J Med 338 8 1998 499 505
12. J.M. Bennett, D. Catovsky, and M.T. Daniel The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations Br J Haematol 47 4 1981 553 561
13. J.M. Bennett, D. Catovsky, and M.T. Daniel Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group Br J Haematol 33 4 1976 451 458
14. D.Z. D'Argenio, and A. Schumitzky A program package for simulation and parameter estimation in pharmacokinetic systems Comput Meth Prog Bio 9 2 1979 115 134
15. S.S. de Graaf, H. Bloemhof, D.E. Vendrig, and D.R. Uges Vincristine disposition in children with acute lymphoblastic leukemia Med Pediatr Oncol 24 4 1995 235 240
16. P. Koopmans, C.E. Gidding, S.S. de Graaf, and D.R. Uges An automated method for the bioanalysis of vincristine suitable for therapeutic drug monitoring and pharmacokinetic studies in young children Ther Drug Monit 23 4 2001 406 409
17. H. Bloemhof, K.N. Van Dijk, S.S. de Graaf, D.E. Vendrig, and D.R. Uges Sensitive method for the determination of vincristine in human serum by high-performance liquid chromatography after on-line column-extraction J Chromatogr 572 1-2 1991 171 179
18. E. Groninger, T. Meeuwsen-De Boer, and P. Koopmans Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia Pediatr Res 52 1 2002 113 118
19. D.Z. D'Argenio Optimal sampling times for pharmacokinetic experiments J Pharmacokinet Biopharm 9 6 1981 739 756
20. C.E. Gidding, G.J. Meeuwsen de Boer, P. Koopmans, D.R. Uges, W.A. Kamps, and S.S. de Graaf Vincristine pharmacokinetics after repetitive dosing in children Cancer Chemother Pharmacol 44 3 1999 203 209
21. V.I. Avramis, K.I. Weinberg, and J.K. Sato Pharmacology studies of 1-beta-d-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug Cancer Res 49 1 1989 241 247
22. H. Kobayashi, Y. Takemura, J.F. Holland, and T. Ohnuma Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukemia cells: mechanism of inoculum effect Biochem Pharmacol 55 8 1998 1229 1234
23. J.A. Sinkule, C.F. Stewart, W.R. Crom, E.T. Melton, G.V. Dahl, and W.E. Evans Teniposide (VM26) disposition in children with leukemia Cancer Res 44 3 1984 1235 1237
24. C.L. Schwartz, E.B. Thompson, and R.D. Gelber Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia J Clin Oncol 19 4 2001 1040 1046